Visual decline in pediatric survivors of brain tumors following radiotherapy

References

• Bhakta N, Liu Q, Ness KK, et al. The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE. Lancet (London, England). 2017;390(10112):2569–2582.
   PubMed Web of Science ®Google Scholar
• Teckle P, Peacock S, McBride ML, et al. Long-term effects of cancer on earnings of childhood, adolescent and young adult cancer survivors – a population-based study from British Columbia, Canada. BMC Health Serv Res. 2018;18(1):826.
   PubMed Web of Science ®Google Scholar
• Williams NL, Rotondo RL, Bradley JA, et al. Late effects after radiotherapy for childhood low-grade glioma. Am J Clin Oncol. 2018;41(3):307–312.
   PubMed Web of Science ®Google Scholar
• Lawrence YR, Li XA, el Naqa I, et al. Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys. 2010;76(3):S20–S7.
   PubMed Web of Science ®Google Scholar
• Mulhern RK, Palmer SL, Merchant TE, et al. Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. J Cin Oncol. 2005;23(24):5511–5519.
   PubMed Web of Science ®Google Scholar
• Vatner RE, Niemierko A, Misra M, et al. Endocrine deficiency as a function of radiation dose to the hypothalamus and pituitary in pediatric and young adult patients with brain tumors. J Cin Oncol. 2018;36(28):2854–2862.
   PubMed Web of Science ®Google Scholar
• Indelicato DJ, Flampouri S, Rotondo RL, et al. Incidence and dosimetric parameters of pediatric brainstem toxicity following proton therapy. Acta Oncologica (Stockholm, Sweden). 2014;53(10):1298–1304.
   PubMed Web of Science ®Google Scholar
• Vieira WA, Weltman E, Chen MJ, et al. Ototoxicity evaluation in medulloblastoma patients treated with involved field boost using intensity-modulated radiation therapy (IMRT): a retrospective review. Radiat Oncol. 2014;9(1):158.
   PubMed Web of Science ®Google Scholar
• Scobioala S, Parfitt R, Matulat P, et al. Impact of radiation technique, radiation fraction dose, and total cisplatin dose on hearing: Retrospective analysis of 29 medulloblastoma patients. Strahlenther Onkol. 2017;193(11):910–920.
   PubMed Web of Science ®Google Scholar
• Bass JK, Hua CH, Huang J, et al. Hearing loss in patients who received cranial radiation therapy for childhood cancer. J Clin Oncol. 2016;34(11):1248–1255.
   PubMed Web of Science ®Google Scholar
• Mayo C, Martel MK, Marks LB, et al. Radiation dose-volume effects of optic nerves and chiasm. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S28–S35.
   PubMed Web of Science ®Google Scholar
• Awdeh RM, Kiehna EN, Drewry RD, et al. Visual outcomes in pediatric optic pathway glioma after conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2012;84(1):46–51.
   PubMed Web of Science ®Google Scholar
• Greenberger BA, Pulsifer MB, Ebb DH, et al. Clinical outcomes and late endocrine, neurocognitive, and visual profiles of proton radiation for pediatric low-grade gliomas. Int J Radiat Oncol Biol Phys. 2014;89(5):1060–1068.
   PubMed Web of Science ®Google Scholar
• Lucas JT, Perkins SM, Raleigh DR, et al. ACNS1721 and ACNS1723 Contouring Atlas. 2019. [cited 2020 Jun 28]. Available from: https://www.qarc.org/cog/ACNS1721_Contouring_Guidelines_20190306.pdf.
   Google Scholar
• Social Security Administration. § 404.1581. Meaning of blindness as defined in the law. Code of Federal Regulations1983 [cited 2019 Jul 1]. Available from: https://www.ssa.gov/OP_Home/cfr20/404/404-1581.htm.
   Google Scholar
• State of California Department of Motor Vehicles. Vision Requirements for Driving Class C Vehicles 2011 [cited 2019 Jul 1]. Available from: https://www.flhsmv.gov/pdf/opengov/vision_ca.pdf.
   Google Scholar
• Michalski J, Vezina G, Burger P, et al. MB-109: preliminary results of COG ACNS0331: a phase III trial of involved field radiotherapy (IFRT) and low dose craniospinarl irradiation (LD-CSI) with chemotherapy in average risk medulloblastoma: a report from the children's oncology group. Neuro Oncol. 2016;18(suppl 3):iii122.
   Google Scholar
• Martel MK, Sandler HM, Cornblath WT, et al. Dose-volume complication analysis for visual pathway structures of patients with advanced paranasal sinus tumors. Int J Radiat Oncol Biol Phys. 1997;38(2):273–284.
   PubMed Web of Science ®Google Scholar
• Whelan KF, Stratton K, Kawashima T, et al. Ocular late effects in childhood and adolescent cancer survivors: a report from the childhood cancer survivor study. Pediatr Blood Cancer. 2010;54(1):103–109.
   PubMed Web of Science ®Google Scholar
• Acharya S, Quesada S, Coca K, et al. Long-term visual acuity outcomes after radiation therapy for sporadic optic pathway glioma. J Neurooncol. 2019;144(3):603–610.
   PubMed Web of Science ®Google Scholar
• Dodgshun AJ, Elder JE, Hansford JR, et al. Long-term visual outcome after chemotherapy for optic pathway glioma in children: Site and age are strongly predictive. Cancer. 2015;121(23):4190–4196.
   PubMed Web of Science ®Google Scholar
• Shofty B, Ben-Sira L, Freedman S, et al. Visual outcome following chemotherapy for progressive optic pathway gliomas. Pediatr Blood Cancer. 2011;57(3):481–485.
   PubMed Web of Science ®Google Scholar
• Rakotonjanahary J, Gravier N, Lambron J, et al. Long-term visual acuity in patients with optic pathway glioma treated during childhood with up-front BB-SFOP chemotherapy – analysis of a French pediatric historical cohort. PLoS One. 2019;14(3):e0212107.
   PubMed Web of Science ®Google Scholar
• Mohan R, Peeler CR, Guan F, et al. Radiobiological issues in proton therapy. Acta Oncol. 2017;56(11):1367–1373.
   PubMed Web of Science ®Google Scholar